What is the MSF Online Journal Club?

The MSF journal club is a forum for debate and discussion of articles relevant to MSF's medical humanitarian programmes.

It aims to bring together MSF programme staff with experts around the world to keep informed of the latest research and opinion around delivering care in resource-limited, emergency Our next MSF Twitter Journal Club is next Friday 1 July at 12.30pm BST.  

 

Subscribe to our mailing list

When and where?

The journal club meets monthly and takes place on Twitter via @MSFsci using the hashtag #MSFjc. Watch this space to find out when the next journal club will be. 

 

Background

In May 2016, the WHO released an update to the DR TB guidelines. The following new recommendations were made (c/w 2011) The resulting assessment of the literature led to a number of new recommendations which were classified as strong or conditional depending on the level of evidence and other factors including risk-benefit and cost-effectiveness.

These caveats are key and why #MSFjc think that it may be useful to discuss some of the new recommendations, which ones you are thinking of implementing and the potential impact on both programs but most importantly, our patients.

 

New to Twitter?

Download our 'how-to guide', which will tell you everything that you need to know about getting started on Twitter. 

Twitter is a social media service where users can post 'tweets' that are 140 characters in length. Users can group tweets by any given topic using a "hashtag", which is a hash sign (#) followed by a given word or phrase. 

For the MSF Online Journal Club all tweets should be marked with #MSFjc and this will create a virtual discussion board, enabling all participants to track our conversation. 

 

Previous journal club discussions

Directly observed therapy for treating tuberculosis / Storify

Classification of antituberculosis drugs: a new proposal based on the most recent evidence / Storify

Optimal Duration of Anti-TB Treatment in Patients With Diabetes: Nine or Six Months?  / Storify

Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China / Storify

Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa / Storify

Effect of the Ebola-virus-disease epidemic on malaria case management in Guinea, 2014: a cross-sectional survey of health facilities / Storify

Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China / Review / Storify

Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine / Review / Storify

Improving Outcomes for Multidrug-Resistant Tuberculosis: Aggressive Regimens Prevent Treatment Failure and Death  / Review / Storify

 

If you require further assistance or have any questions about the journal club please contact Kim West at kim.west@london.msf.org

 

Fill out my online form.

The latest news straight to your inbox

Short on time? Get the latest news, stories and blogs sent to your inbox each month.

Sign-up here